Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Non-allosteric Inhibition of Enolase 1 Impedes Growth of Triple-Negative Breast Cancer

ABSTRACT: 1. Cellular Thermal Shift Assay (CETSA): MDA-MB-231 cells were treated for 6h with DMSO or SU212 and incubated at different temperatures and protein differences in the soluble fractions were determined. 2. Quantitative Proteomics: MDA-MB-231, MDA-MB-468, and BT549 cells were treated with DMSO (vehicle control) or SU212 (novel small molecule drug candidate). Quantitative proteomics analysis was performed on cell lysates.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Breast Cancer Cell Line

DISEASE(S): Breast Cancer

SUBMITTER: Sharon Pitteri

LAB HEAD: Sharon Pitteri

PROVIDER: PXD061466 | Pride | 2025-10-10

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Dhanir_TMT_Sample1_061120_01.raw	Raw
	Dhanir_TMT_Sample1_061120_02.raw	Raw
	Dhanir_TMT_Sample1_061120_03.raw	Raw
	Dhanir_TMT_Sample2_061120_01.raw	Raw
	Dhanir_TMT_Sample2_061120_02.raw	Raw

Items per page:

1 - 5 of 17

Similar Datasets

Proteomics of Triple Negative Breast Cancer Cells Treated with SU056

Project description:1. Quantitative Proteomics: MDA-MB-231, MDA-MB-468, and MCF12A cells were treated with DMSO (vehicle control) or SU056 (novel small molecule drug candidate). Quantitative proteomics analysis was performed on cell lysates. 2. Cellular Thermal Shift Assay (CETSA): MDA-MB-231 cells were treated with DMSO or SU056 and incubated at different temperatures and protein differences in the resulting soluble and insoluble fractions were determined.3. Cellular Thermal Shift Assay (CETSA): MDA-MB-231 YBOX1 KD cells were treated with DMSO or SU056 and incubated at different temperatures and protein differences in the soluble fractions were determined.

2024-04-04 | PXD042380 | Pride

Gene expression profiling of triple-negative breast cancer cells and liver cancer cells perturbed by BET inhibitor JQ1

Project description:To obtain the gene expression profiles of triple-negative breast cancer MDA-MB-231 cells and liver cancer HepG2 cells perturbed by the BET inhibitor JQ1, we treated MDA-MB-231 and HepG2 cells with either DMSO (control) or 10 μM JQ1 for 24 hours. By comparing the expression profiles of DMSO-treated cells with those treated with JQ1, we can identify the genes affected by JQ1.

2025-08-22 | GSE294293 | GEO

Roscovitinen suppresses TRIM32 nuclear translocaton via STAT3 signaling

Project description:Next Generation Sequencing Facilitates Quantitative Analysis of MDA-MB-231 cells treated with Roscovitinen and DMSO

2024-07-25 | GSE210030 | GEO

Phosphoproteomics data of the Anti-Proliferative Activity of Safranal on Triple-Negative Breast Cancer Cell

Project description:We conducted a combining isobaric tag-based TMT labeling followed by titanium dioxide (TiO2)-based enrichment of phosphopeptides as phosphoproteomics study on MDA-MB-231 treated with safranal.

2022-08-30 | PXD036323 | Pride

RNA-sequencing of MDA-MB-231 breast cancer cells with and without treatment of BAY 2506856

Project description:MDA-MB-231 cancer cells were treated for 24h with DMSO or BAY 2506856. RNA-sequencing was performed to identify changes induced by treatment on the transcriptome level.

2024-02-01 | GSE243122 | GEO

Novel azetidine-based Stat3 inhibitors induce misfolded protein response, endoplasmic reticulum stress and mitophagy, and inhibit breast tumor growth in vivo

Project description:To identify differentially expressed genes and pathways in human breast cancer cell line MDA-MB-231 cells that are treated with a novel Stat3 inhibitor or DMSO control.

2022-07-12 | GSE180123 | GEO

Oncohistone mutations occur at functional sites of regulatory ADP-ribosylation: the role of oncohistone mutations in transcriptional regulation [ChIP-Seq]

Project description:H2BK12ac ChIP-seq were performed in MDA-MB-231 cells ectopically expressing FLAG-tagged WT, D51A, or D51N H2B ± treatment with A485 (5 M, 2 hours) or vehicle (DMSO).

2022-08-02 | GSE180459 | GEO

Acetylomics data of the Anti-Proliferative Activity of Safranal on Triple-Negative Breast Cancer Cell

Project description:We conducted a combining isobaric tag-based TMT labeling followed by enrichment of lysine acetylated peptides by Acetyl-Lysine Immunoprecipitation (IP) method as Acetylomics study on MDA-MB-231 treated with safranal.

2022-08-30 | PXD036333 | Pride

Expression data from MDA-MB-231 breast cancer cell lines exposed to DMSO control and UF010

Project description:Breast cancer cell line MDA-MB-231 was treated with DMSO or UF010, a novel HDAC inhibitor for 24 hours. The impact of UF010 treatment on global gene expression was determined. We used Affymetrix Human Transcriptome Array 2.0 (HTA-2_0) to analyze genes that were up or downregulated upon UF010 exposure. MDA-MB-231 cells were treated with DMSO (control) or 1.0 ÂµM of UF010 for 24 hours.Total RNAs were isolated for hybridization on Affymetrix microarrays.

2015-02-19 | E-GEOD-56823 | biostudies-arrayexpress

Tang2019 - Pharmacology modelling of AURKB and ZAK interaction in TNBC

Project description:Aurora Kinase B and ZAK interaction model Equivalent of the stochastic model used in "Network pharmacology model predicts combined Aurora B and ZAK inhibition in MDA-MB-231 breast cancer cells" by Tang et. al. 2018. The only difference is cell division and partitioning of the components, which are available in the original model for SGNS2.

2024-09-02 | BIOMD0000000940 | BioModels

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data